Chengbin Wu

Chengbin Wu has a strong background in the biopharmaceutical industry with a focus on research and development. Chengbin currently serves as the CEO of EpimAb Biotherapeutics, Inc. since May 2016. Prior to this, they held the position of CSO and President of R&D at Shanghai CP Guojian Pharmaceutical Co., Ltd. from August 2013 to April 2016. Chengbin also worked as Senior Vice President of Biologics and later as VP Biologics at Shanghai Genomics Research Institute from February 2010 to August 2013. Before their time in China, Wu worked at AbbVie as Associate Research Fellow, where they were involved in therapeutic antibody and biologics development as a project leader. Chengbin also contributed to the development of novel biologics technology known as dual variable domain immunoglobulin (DVD-Ig). Prior to their industry experience, Wu completed a postdoctoral fellowship at Harvard Medical School where they made notable contributions to T cell responses and differentiation research. Overall, Wu has a strong research background and has held leadership positions in various biopharmaceutical companies.

Chengbin Wu completed a Bachelor of Engineering degree in Biochemical Engineering from East China University of Science and Technology from 1985 to 1989. Chengbin then pursued a doctoral degree in Biochemistry and Molecular Biology at The University of Georgia from 1993 to 1997. Following this, they furthered their education by completing a Postdoctoral Fellowship in Molecular Immunology at Harvard Medical School from 1997 to 2000.